Literature DB >> 24138034

The role of genetics in the pathogenesis of periocular cutaneous neoplasms: implications for targeted therapy.

Nahyoung Grace Lee1, Leo A Kim, Suzanne K Freitag.   

Abstract

In the past, cutaneous malignancies of the periocular region were primarily treated surgically with few other options. As the genetic bases of these tumors have become elucidated, targeted therapies aimed specifically at pathways that are felt to be responsible for cellular proliferation and uncontrolled growth have emerged with new promise. This review contains a summary of the various genetic implications of cutaneous neoplasms as well as their corresponding targeted systemic therapies.

Entities:  

Mesh：

Year:  2013        PMID： 24138034      PMCID： PMC4342750          DOI： 10.3109/08820538.2013.825278

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN： 0882-0538            Impact factor:   1.975


  56 in total

1.  A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

Authors:  Carol M Lewis; Bonnie S Glisson; Lei Feng; Fiona Wan; Ximing Tang; Ignacio I Wistuba; Adel K El-Naggar; David I Rosenthal; Mark S Chambers; Robert A Lustig; Randal S Weber
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

2.  Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.

Authors:  Eve Maubec; Peter Petrow; Isabelle Scheer-Senyarich; Pierre Duvillard; Ludovic Lacroix; Julien Gelly; Agnès Certain; Xavier Duval; Béatrice Crickx; Valérie Buffard; Nicole Basset-Seguin; Pierre Saez; Anne-Bénédicte Duval-Modeste; Henri Adamski; Sandrine Mansard; Florent Grange; Anne Dompmartin; Sandrine Faivre; France Mentré; Marie-Françoise Avril
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

3.  Development of α-melanocortin analogs for melanoma prevention and targeting.

Authors:  Zalfa A Abdel-Malek
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

4.  A phase II study of gefitinib in patients with metastatic melanoma.

Authors:  Sapna P Patel; Kevin B Kim; Nicholas E Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Victor G Prieto; Menashe Bar-Eli; Maya Zigler; Andrey Dobroff; Yulia Bronstein; Roland L Bassett; Anna G Vardeleon; Agop Y Bedikian
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

5.  Development of a DNA vaccine targeting Merkel cell polyomavirus.

Authors:  Qi Zeng; Bianca P Gomez; Raphael P Viscidi; Shiwen Peng; Liangmei He; Barbara Ma; T-C Wu; Chien-Fu Hung
Journal:  Vaccine       Date:  2011-12-29       Impact factor: 3.641

6.  EGFR in melanoma: clinical significance and potential therapeutic target.

Authors:  Barbara Boone; Koen Jacobs; Liesbeth Ferdinande; Jasmien Taildeman; Jo Lambert; Marc Peeters; Marc Bracke; Patrick Pauwels; Lieve Brochez
Journal:  J Cutan Pathol       Date:  2011-02-24       Impact factor: 1.587

Review 7.  Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

Authors:  Pablo Uribe; Sergio Gonzalez
Journal:  Pathol Res Pract       Date:  2011-04-29       Impact factor: 3.250

8.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Authors:  Jun Guo; Lu Si; Yan Kong; Keith T Flaherty; Xiaowei Xu; Yanyan Zhu; Christopher L Corless; Li Li; Haifu Li; Xinan Sheng; Chuanliang Cui; Zhihong Chi; Siming Li; Mei Han; Lili Mao; Xuede Lin; Nan Du; Xiaoshi Zhang; Junling Li; Baocheng Wang; Shukui Qin
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

9.  The significance of DNA mismatch repair genes in the diagnosis and management of periocular sebaceous cell carcinoma and Muir-Torre syndrome.

Authors:  Brent J Gaskin; Bertie S Fernando; Charlotte A Sullivan; Kevin Whitehead; Timothy J Sullivan
Journal:  Br J Ophthalmol       Date:  2011-10-06       Impact factor: 4.638

Review 10.  Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma.

Authors:  Jean Y Tang
Journal:  Semin Cutan Med Surg       Date:  2011-12
View more
  1 in total

1.  Evaluation of Patched-1 Protein Expression Level in Low Risk and High Risk Basal Cell Carcinoma Subtypes.

Authors:  Rowida Almomani; Mariam Khanfar; Khaldon Bodoor; Firas Al-Qarqaz; Mohammad Alqudah; Hanan Hammouri; Asma Abu-Salah; Yazan Haddad; Wisam Al Gargaz; Ziyad Mohaidat
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.